Immaculé
One Stop Solution
Concept to Commercialization
The Future of Immacule
As we remain dedicated to innovation, quality and delivering advanced healthcare solutions, we are expanding our product manufacturing capabilities. With an investment of USD 150 million, this expansion is scheduled for completion by 2024 and will cater to the diverse needs of the industry. Through this expansion we will bring in a new Freeze-Drying capacity, Ophthalmic capacity, Pre-Filled Syringe and Cartridge capacity as well as mark our entry into the production of oncology injectables.
Liquid/Lyophilized Vials
Capability: 1 mL to 100 mL
Ophthalmic
Capability: 1 mL to 30 mL
Pre-Filled Syringe / Cartridge
Capability: 1 mL to 10 mL
Oncology Liquid/Lyophilized Vials
Capability: 1 mL to 100 mL
Liquid/Lyophilized Vials
Capability: 1 mL to 100 mL
Ophthalmic
Capability: 1 mL to 30 mL
Pre-Filled Syringe / Cartridge
Capability: 1 mL to 10 mL
Oncology Liquid/Lyophilized Vials
Capability: 1 mL to 100 mL
60M
Liquid/Lyophilized Vials
30M
Ophthalmic
24M
PFS/Cartridge
60M
Oncology Liquid/Lyophilized Vials
Trusted Technology Investment: Paving the Way for Superior Products
